Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study
Why the study?
Longer-term follow-up was needed to confirm whether early functional, quality of life, and right-heart reverse remodelling improvements after transcatheter tricuspid valve intervention are sustained.
Does transfemoral transcatheter tricuspid valve replacement improve tricuspid regurgitation and functional outcomes in patients with symptomatic ≥moderate tricuspid regurgitation?
Population
176 patients with ≥moderate, symptomatic TR despite medical therapy
Comparison
Transfemoral transcatheter TV replacement (single arm)
Design
Prospective, single-arm, multicentre study
Follow-up
One year
Authors
Discussion
Loading...
Member takes
Implication
May improve symptoms and function in severe TR; hypothesis-generating pending randomized trials.
Structured PICO
Does transfemoral transcatheter tricuspid valve replacement improve tricuspid regurgitation and functional outcomes in patients with symptomatic ≥moderate tricuspid regurgitation?
P
Population
176 patients with ≥moderate, symptomatic tricuspid regurgitation despite medical therapy, mean age 78.7 years, 71.0% female, 88.0% ≥ severe TR, 75.4% NYHA class III-IV.
I
Intervention
Transfemoral EVOQUE transcatheter tricuspid valve replacement
O
Outcome
Major adverse events, reduction in TR grade and haemodynamic outcomes by echocardiography, and clinical, functional, and quality-of-life parameters at one year
Transfemoral EVOQUE transcatheter tricuspid valve replacement provides sustained TR reduction and significant clinical and functional improvements at one year in a highly comorbid population.
Cite This Study
Kodali et al. (2023) studied this question.